文献速递心律失常血脂与心血管预防

房颤患者创伤后恢复口服抗凝与卒中及出血风险:全国性队列研究

Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study.
PubMed 文献 · Eur Heart J · 2018-01-01

丹麦全国注册研究纳入4541例口服抗凝治疗的房颤创伤患者,90天内60.6%恢复VKA、16.7%恢复NOAC、22.7%未恢复。与未恢复相比,恢复VKA或NOAC与全因死亡和缺血性卒中风险降低相关,大出血风险增加,但复发性创伤风险无显著增加。

要点

  • 房颤患者创伤后恢复VKA或NOAC与全因死亡和缺血性卒中风险降低相关。
  • 恢复VKA或NOAC与大出血风险增加相关,但复发性创伤风险无显著增加。
  • 创伤后停用口服抗凝可能并不合理。

核心结论

  • 房颤患者创伤后恢复VKA或NOAC与全因死亡和缺血性卒中风险降低相关,大出血风险增加,但复发性创伤风险无额外增加。
  • 创伤后停用口服抗凝可能并不合理。

研究设计与样本

  • 丹麦全国注册研究(2005-16年),纳入4541例口服抗凝治疗的房颤创伤患者。
  • 创伤定义为创伤性脑损伤、髋部骨折或创伤性躯干/腹部损伤。
  • 随访自出院后90天开始,采用时变多因素Cox回归分析比较。

主要发现

  • 出院后90天内60.6%恢复VKA(中位年龄80,CHA2DS2-VASc=4,HAS-BLED=2),16.7%恢复NOAC(中位年龄81,CHA2DS2-VASc=4,HAS-BLED=2),22.7%未恢复(中位年龄81,CHA2DS2-VASc=4,HAS-BLED=3)。
  • 9.5%的患者从VKA转换为NOAC。
  • 2009年以来口服抗凝恢复趋势增加(P<0.0001),尤其是NOAC(P<0.0001)。
  • 与未恢复相比,恢复VKA和NOAC的全因死亡HR分别为0.48(95%CI 0.42-0.53)和0.55(95%CI 0.47-0.66)。
  • 与未恢复相比,恢复VKA和NOAC的缺血性卒中HR分别为0.56(95%CI 0.43-0.72)和0.54(95%CI 0.35-0.82)。

临床怎么用

  • 房颤患者发生创伤后,不应常规停用口服抗凝,应考虑恢复VKA或NOAC治疗。
  • 恢复抗凝时需权衡缺血性卒中与出血风险,但复发性创伤风险未见额外增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We examined the risks of all-cause mortality, stroke, major bleeding, and recurrent traumatic injury associated with resumption of vitamin K antagonists (VKAs) and non-VKAs oral anticoagulants (NOACs) following traumatic injury in atrial fibrillation (AF) patients. METHODS AND RESULTS: This was a Danish nationwide registry-based study (2005-16), including 4541 oral anticoagulant (OAC)-treated AF patients experiencing traumatic injury (defined as traumatic brain injury, hip fracture, or traumatic torso or abdominal injury). Within 90 days following discharge from traumatic injury, 60.6% resumed VKA (median age = 80, CHA2DS2-VASc = 4, HAS-BLED = 2), 16.7% resumed NOAC (median age = 81, CHA2DS2-VASc = 4, HAS-BLED = 2), and 22.7% did not resume OAC treatment (median age = 81, CHA2DS2-VASc = 4, HAS-BLED = 3). Switch from VKA to NOAC occurred among 9.5%. Since 2009, the trend in OAC resumption increased (P-value <0.0001), in particular with NOACs (P-value <0.0001). Follow-up started 90 days after discharge, and time-varying multiple Cox regression analyses were used for comparisons. Compared with non-resumption, VKA and NOAC resumption were associated with lower hazard [95% confidence interval (CI)] of all-cause mortality [hazard ratio (HR) 0.48 (0.42-0.53) and HR 0.55 (0.47-0.66), respectively] and ischaemic stroke [HR 0.56 (0.43-0.72) and HR 0.54 (0.35-0.82), respectively], increased major bleeding hazard [HR 1.30 (1.03-1.64) and HR 1.15 (0.81-1.63), respectively], and similar hazard of recurrent traumatic injury [HR 0.93 (0.73-1.18) and HR 0.87 (0.60-1.27), respectively]. CONCLUSION: AF patients resuming VKA and NOAC treatment following traumatic injury have lower hazard of all-cause mortality and ischaemic stroke, increased hazard of major bleeding but without additional hazards of recurrent traumatic injury. Withholding OAC following a traumatic injury in AF patients may not be warranted.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Staerk L, Fosbøl EL, Lamberts M, et al. Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J. 2018. PMID: 29165556. doi:10.1093/eurheartj/ehx598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。